216 related articles for article (PubMed ID: 33971800)
21. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
22. Decitabine Compared With Conventional Regimens in Older Patients With Acute Myeloid Leukemia: A Meta-Analysis.
Bian MR; Yang HS; Lin GQ; Wan Y; Wang L; Si YJ; Zhang XX; Wang M; Zhou H; Zhao GS; Zhang YM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):e636-e648. PubMed ID: 31645307
[TBL] [Abstract][Full Text] [Related]
23. Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia.
Chen X; Zhu H; Qiao C; Zhao S; Liu L; Wang Y; Jin H; Qian S; Wu Y
Hematology; 2021 Dec; 26(1):111-122. PubMed ID: 33491606
[TBL] [Abstract][Full Text] [Related]
24. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
26. [Comparision of Mutational Spectrum between Elderly and Young Adults with Acute Myeloid Leukemia Based on Next Generation Sequencing].
Wang WM; Li YF; Sun L; Jiang ZX; Wan DM; Ma J; Gan SL; Wang F; Cao WJ; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):12-17. PubMed ID: 32027246
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].
Chen D; Lu Y; Yan RZ; Ye PP; Zhang YS; Ma JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):390-395. PubMed ID: 30998143
[TBL] [Abstract][Full Text] [Related]
28. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
[TBL] [Abstract][Full Text] [Related]
29. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
30. Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.
Kao HW; Liang DC; Wu JH; Kuo MC; Wang PN; Yang CP; Shih YS; Lin TH; Huang YH; Shih LY
Neoplasia; 2014 Jun; 16(6):481-8. PubMed ID: 25022553
[TBL] [Abstract][Full Text] [Related]
31. Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia.
Wu S; Dai Y; Zhang Y; Wang X; Wang L; Ma D; Zhang L; Pang Y; Jiao Y; Niu M; Xu K; Ke X; Shi J; Cheng Z; Fu L
Cancer Gene Ther; 2018 Aug; 25(7-8):207-213. PubMed ID: 29904089
[TBL] [Abstract][Full Text] [Related]
32. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
Bocchia M; Candoni A; Borlenghi E; Defina M; Filì C; Cattaneo C; Sammartano V; Fanin R; Sciumè M; Sicuranza A; Imbergamo S; Riva M; Fracchiolla N; Latagliata R; Caizzi E; Mazziotta F; Alunni G; Di Bona E; Crugnola M; Rossi M; Consoli U; Fontanelli G; Greco G; Nadali G; Rotondo F; Todisco E; Bigazzi C; Capochiani E; Molteni A; Bernardi M; Fumagalli M; Rondoni M; Scappini B; Ermacora A; Simonetti F; Gottardi M; Lambertenghi Deliliers D; Michieli M; Basilico C; Galeone C; Pelucchi C; Rossi G
Hematol Oncol; 2019 Oct; 37(4):447-455. PubMed ID: 31385337
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.
He PF; Zhou JD; Yao DM; Ma JC; Wen XM; Zhang ZH; Lian XY; Xu ZJ; Qian J; Lin J
Oncotarget; 2017 Jun; 8(25):41498-41507. PubMed ID: 28489568
[TBL] [Abstract][Full Text] [Related]
34. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
[No Abstract] [Full Text] [Related]
36. Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia.
Li F; Li N; Wang A; Liu X
Clin Interv Aging; 2022; 17():1187-1197. PubMed ID: 35967966
[TBL] [Abstract][Full Text] [Related]
37. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
[TBL] [Abstract][Full Text] [Related]
38. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
39. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.
Zheng L; Huang L; Hui Y; Huang L; Li Y; Shang Z; Wei J; Wang Z; Mao X; Wang Y; Xiao M; Zhang D
Int J Oncol; 2020 Jun; 56(6):1521-1528. PubMed ID: 32236618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
